Articles related to Infectious Disease Pharmacy (BCIDP)

The FDA approved updated 2026-2027 formulations of Pfizer-BioNTech, Moderna, and Novavax COVID-19 vaccines targeting the XFG variant, aligning with advisory committee recommendations for the upcoming vaccination season.

A multisociety consensus paper outlines hospital-level strategies to improve sepsis outcomes, emphasizing diagnostic stewardship, antimicrobial optimization, surveillance, infection prevention, and multidisciplinary infrastructure while prioritizing interventions judged most feasible and impactful for broad implementation.

The FDA has approved the first generic version of baloxavir marboxil, a single-dose influenza antiviral noninferior to oseltamivir, ahead of the 2026-2027 flu season.

The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.